Drug intelligence / Profile preview

Oraguard C1

Development stage: Preclinical
Lead developer: Swalife Biotech
Modality: Targeted Liposomes → Liposomes → Lipid-based Nanoparticles → Nanoparticles → Drug Delivery Systems, Polymer-based Nanoparticles → Nanoparticles → Drug Delivery Systems
Administration: Topical

Overview

Oraguard C1 is a preclinical-stage precision onco-formulation developed by Swalife Biotech. It specifically targets Chloride Intracellular Channel 1 (CLIC1), a protein involved in cell cycle regulation and often overexpressed in various cancers, including oral squamous cell carcinoma. The drug is intended for oral health applications and mucosal chemoprevention, aiming to prevent the malignant transformation of oral lesions. By modulating CLIC1, Oraguard C1 seeks to provide a targeted approach to preventing the progression of pre-malignant oral mucosal conditions to invasive cancer.

Targets

CLIC1 (Chloride intracellular channel protein 1)

Beyond the preview

Go deeper on Oraguard C1.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on Oraguard C1.

Explore the full profile